Request Deal Involvement

Goldman Sachs led the $158m Series B round in TORL BioTherapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Schulte Roth & Zabel

legal advisors

Schulte Roth & Zabel

Latham & Watkins

legal advisors

Latham & Watkins

or

Principals

BRISTOL MYERS SQUIBB COMPANY

bidder

BRISTOL MYERS SQUIBB COMPANY

TORL BIOTHERAPEUTICS LLC

target

TORL BIOTHERAPEUTICS LLC

DEEP TRACK CAPITAL

bidder

DEEP TRACK CAPITAL

PERCEPTIVE XONTOGENY VENTURE FUND

bidder

PERCEPTIVE XONTOGENY VENTURE FUND

UC INVESTMENTS

bidder

UC INVESTMENTS

MOORE STRATEGIC VENTURES

bidder

MOORE STRATEGIC VENTURES

BLUE OWL HEALTHCARE OPPORTUNITIES (EX-COWEN HEALTHCARE INVESTMENTS)

bidder

BLUE OWL HEALTHCARE OPPORTUNITIES (EX-COWEN HEALTHCARE INVESTMENTS)

VERTEX VENTURES

bidder

VERTEX VENTURES

ALEXANDRIA VENTURE INVESTMENTS

bidder

ALEXANDRIA VENTURE INVESTMENTS

GOLDMAN SACHS ASSET MANAGEMENT

bidder

GOLDMAN SACHS ASSET MANAGEMENT

OCV PARTNERS

bidder

OCV PARTNERS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Goldman Sachs led the $158m Series B round in TORL BioTherapeutics.